Keywords: tranexamic acid total knee arthroplasty total hip arthroplasty venous thromboembolic event arterial thromboembolic event a b s t r a c t Background: Tranexamic acid (TXA) is effective in reducing blood loss in total joint arthroplasty (TJA), but concerns still remain regarding the drug's safety. The purpose of this direct meta-analysis was to evaluate and establish a basis for the safety recommendations of the combined clinical practice guidelines on the use of TXA in primary TJA. Methods: A search was completed for studies published before July 2017 on TXA in primary TJA. We performed qualitative and quantitative homogeneity testing and a direct comparison meta-analysis. We used the American Society of Anesthesiologists (ASA) score of 3 or greater as a proxy for patients at higher risk for complications in general and performed a meta-regression analysis to investigate the influence of comorbidity burden on the risk of arterial thromboembolic event and venous thromboembolic event (VTE). Results: Topical, intravenous, and oral TXA were not associated with an increased risk of VTE after TJA. In addition, meta-regression demonstrated that TXA use in patients with an ASA status of 3 or greater was not associated with an increased risk of VTE after total knee arthroplasty. Conclusion: Although most studies included in our analysis excluded patients with a history of prior thromboembolic events, our findings support the lack of evidence of harm from TXA administration in patients undergoing TJA. Moderate evidence supports the safety of TXA in patients undergoing total knee arthroplasty with an ASA score of 3 or greater. The benefits of using TXA appear to outweigh the potential risks of thromboembolic events even in patients with a higher comorbidity.
Over the past several years, antifibrinolytic drugs have been used extensively to reduce blood loss and the risk of transfusion after both total hip and total knee arthroplasties (THA and TKA), with numerous randomized trials supporting their efficacy [1e4] . One antifibrinolytic drug, aprotinin, was found to be more effective at reducing blood loss than both tranexamic acid (TXA) and ε-aminocaproic acid (EACA), but was removed from the market in 2008 because of an association with a significant increase in cardiovascular complications and death among cardiac surgery patients [5] . As TXA is significantly more potent than EACA and achieves higher synovial concentrations, its use has become more popular in orthopedic surgery [6] .
TXA works by competitively inhibiting the activation of plasminogen to prevent fibrin degradation [7, 8] . Given the clotstabilizing properties of antifibrinolytic drugs, there is concern about the potential of these drugs to increase the risk of an arterial or venous thromboembolic event (ATE or VTE). Retrospective investigations of the safety regarding TXA administration in patients undergoing lower extremity total joint arthroplasty (TJA) has not demonstrated an increased risk of thromboembolic events with or without a prior history of a thromboembolic event [9e12] . However, the scientific literature lacks high-level evidence to allow evaluation of the safety of TXA with a sufficient population size to exclude an increased risk of thromboembolic events associated with the administration of TXA.
The American Association of Hip and Knee Surgeons (AAHKS), American Academy of Orthopaedic Surgeons (AAOS), Hip Society, Knee Society, and American Society of Regional Anesthesia and Pain Medicine (ASRA) have collaborated in the development of a clinical practice guideline on the use of TXA in TJA. We performed a systematic review and meta-analysis of randomized clinical trials to evaluate the safety of TXA administration in THA and TKA to support the clinical practice guideline. The aim of our study was to compare the risk of VTE and ATE for patients undergoing primary TJA treated with TXA, compared with those not treated with TXA.
Materials and Methods
The systematic review and meta-analysis was designed and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [13] .
Search Methodology
A research librarian was used to assist with the completion of the literature search of the Ovid MEDLINE, EMBASE, Cochrane Reviews, Scopus, and Web of Science databases. Initially, the search strategy established the primary search themesd"arthroplasty" and "tranexamic acid" followed by the use of Exploded Medical Subjection Headings terms and Boolean operators. We developed search strategies that were individualized for each database (Appendix B). Because of a limitation of access to all databases, searches for EMBASE and Web of Science included all published articles before October 2016, whereas Ovid MEDLINE, Cochrane Reviews, and Scopus included all published articles before July 2017. In addition, the bibliographies of relevant publications such as reviews and meta-analyses were evaluated for supplementary publications and to help validate the quality of our search methodology.
Study Selection Criteria
The inclusion and exclusion criteria were altered based on the thromboembolic outcome being investigated in the meta-analysis. Overlapping inclusion criteria for VTE and ATE were the following:
(1) All study participants must have undergone either a primary TKA or THA and (2) At least one of the treatment arms of the study must have compared the use of TXA with a control group that received no antifibrinolytic agent. Publications that had multiple treatment arms with other antifibrinolytic agents like EACA were acceptable, but only the treatment arms with TXA or placebo would be included in the analysis. No exclusions were made regarding dosing route (ie, intra-articular/topical vs intravenous [IV]), administered dose (dosage amount and bolus vs continuous infusion), or timing of administration (preoperative, intraoperative, or postoperative) as none of these variables are considered to materially alter the risk of VTE.
The inclusion criteria specific to the investigation of VTE reported outcomes related to VTE including symptomatic deep venous thrombosis (proximal lower extremity deep venous thrombosis) or pulmonary embolism. As for the investigation of ATE, the study must have reported outcomes related to ATE including cerebrovascular accident (CVA) or myocardial infarction (MI). In addition, no limitations were imposed based on the form of postoperative VTE chemoprophylaxis used in the study.
The exclusion criteria for both VTE and ATE investigations were the following: (1) Patients undergoing a revision hip or knee arthroplasty or arthroplasties of any other joint; (2) Study subjects undergoing simultaneous or staged bilateral primary TKA or THA; (3) Secondary source articles including review articles, systematic reviews, meta-analyses, expert opinions; and (4) Published abstracts from the proceedings of a scientific meeting, unless an accompanying published manuscript was also available.
Data Collection
Two authors independently completed the title and abstract screening to eliminate duplicate publications and studies meeting any exclusion criteria. Any doubt regarding the inclusion or exclusion status of a study meant that it was included for full manuscript review. Two authors independently performed a full manuscript review to assess the inclusion or exclusion status of the remaining publications from the title and abstract screening.
The AAOS Department of Research, Quality, and Scientific Affairs completed the assessment of the quality and data extraction for all the publications from the full manuscript review following the process outlined in the AAOS Clinical Practice Guidelines and Systematic Review Methodology [14] . The quality assessment of the publications was performed based on an appraisal of the randomization, allocation concealment, blinding, completeness of outcome data, selective reporting, and conflict of interest. Because of the significant amount of published literature on the use of TXA in TJA, we further limited the pool of publications to only include randomized clinical trials of high quality and a single moderate quality study.
Study outcomes were monitored to investigate for consistency in the reporting of outcomes between the publications. VTE and ATE were all confirmed with various imaging modalities including ultrasound and computed tomography scan; however, no limitations were applied based on the method of screening for deep venous thrombosis in the randomized clinical trials of the metaanalyses.
Statistical Analysis STATA 12.1 software (StataCorp, College Station, TX) was used to run direct meta-analysis when 4 or more authors provided data regarding VTE or ATE from a single treatment comparison. To minimize qualitative heterogeneity, articles examining equal treatment comparisons with consistent dosing and timing were included in the analysis. Quantitative heterogeneity coefficients for VTE and ATE outcomes were reported for all treatment comparisons. Many included data points did not have a risk ratio (RR) generated because of there being zero events for both treatment groups. However, these data were still used in the overall RR calculation. Ninety-two percent of the studies in the meta-analysis comparing TXA administration with placebo excluded patients with a prior history of a thromboembolic event [15e92] . Because the results of the meta-analysis would not be applicable to patients with comorbidities associated with a higher risk of a thromboembolic event, metaregression analysis was used to assess the influence of comorbidity burden on the risk of thromboembolic events and the administration of TXA. Because individual comorbidities such as prior MI, CVA, peripheral vascular disease, VTE, or vascular stent placement were not commonly reported in publications, the American Society of Anesthesiologist (ASA) status was used as a proxy for the presence of comorbidities associated with an increased risk of a thromboembolic event. Consistent with prior publications, an ASA status of 3 or greater was considered to represent "high-risk" for a thromboembolic event [9e11]. Metaregression analysis was performed using the publications reporting ASA status among the study participants. We compared study populations of patients with more than 50% ASA status of 3 or greater with study populations of patients with more than 50% ASA status of 1 or 2. Because of the limited number of publications reporting both ASA status and the outcome of ATE, metaregression analysis was only performed for VTE. Metaregression analysis was run in STATA 12.1 software to investigate for any influence of the quality appraisal fields and ASA status of the patient populations on the risk of VTE. A P value >.05 was considered significant.
Using the data on the rates of VTE, the number needed to harm was calculated as the inverse of the attributable risk per patient. Because additional sister studies were performed on the efficacy of TXA, we used the data on the rates of transfusion to calculate the number needed to treat as the inverse of the absolute risk reduction per patient.
Results
The search strategy resulted in 2113 publications that underwent title and abstract screening. As a result of the initial screening, 1463 publications were a duplicate or met the exclusion criteria. Among the remaining 650 publications that underwent a full manuscript review, 361 publications met the exclusion criteria, whereas the remaining 289 publications underwent data extraction and quality assessment. After completion of the quality assessment, only randomized clinical trials representing the highest quality of evidence remained, leaving 79 publications with 7164 patients to be included for our meta-analysis of VTE or ATE.
Meta-Analysis of VTEs
After the quality assessment, 78 randomized clinical trials were available for the meta-analysis of VTE encompassing 7044 patients (Table 1) [15e92]. Published randomized clinical trials included comparisons between placebo and IV, topical, oral, combined IV/ topical, or combined IV/oral TXA. Direct comparisons of VTE for meta-analysis were performed with THA or TKA publications when 4 or more publications investigated the same TXA intervention. The resulting THA comparisons were between placebo and IV or topical TXA. In the TKA publications, the analysis was performed for comparisons between placebo and IV, topical, or oral TXA. In addition, a combined analysis of all hip and knee arthroplasty studies was performed to provide a larger study population for IV and topical TXA compared with placebo.
Total Hip Arthroplasty
Among 22 randomized clinical trials comparing IV TXA with a placebo, the rates of VTE were 2.8% and 2.1%, respectively (RR 1.20; 95% confidence interval [CI], 0.62-2.33; I 2 ¼ 0%; Fig. 1A) . Similarly, topical TXA demonstrated no difference in the rates of VTE compared with a placebo at 1.2% and 1.5%, respectively (RR 1.0; 95% CI, 0.21-4.89; I 2 ¼ 0%; Fig. 1B ).
Total Knee Arthroplasty
Among the 35 randomized clinical trials comparing IV TXA with a placebo, the rates of VTE were 2.8% and 3.1%, respectively (RR 0.87; 95% CI, 0.58-1.32; I 2 ¼ 0%; Fig. 2A) . Likewise, the metaanalysis of 25 studies on topical TXA had a similar rate of VTE compared with placebo at 2.6% and 2.9%, respectively (RR 0.89; 95% CI, 0.54-1.48; I 2 ¼ 0%; Fig. 2B ). Only 5 studies were analyzed to compare VTE rates between oral TXA and placebo, but no difference was observed at 3.3% and 3.6%, respectively (RR 0.88; 95% CI, 0.38-2.04; I 2 ¼ 0%; Fig. 2C ).
Combined THA and TKA Among the 58 randomized clinical trials comparing IV TXA with a placebo, the number of patients in each group was 2131 and 2137, respectively. The rates of VTE were equivalent at 2.8% for both IV TXA and placebo (RR 0.98; 95% CI, 0.69-1.39; I 2 ¼ 0%; Fig. 3A) . The 31 randomized studies comparing topical TXA and placebo had 1509 and 1502 patients per group, respectively. Like the results of IV TXA, topical TXA had a similar rate of VTE compared with placebo at 2.2% and 2.5%, respectively (RR 0.89; 95% CI, 0.56-1.41; I 2 ¼ 0%; Fig. 3B ).
Meta-Analysis of ATEs
ATEs were rarely reported as a complication in the randomized clinical trials. After the quality assessment, 9 randomized clinical trials encompassing 817 patients were available for the metaanalysis (Table 2) [16, 30, 37, 38, 65, 67, 68, 90, 93] . Published randomized clinical trials included comparisons between placebo and IV, topical, oral, or combined IV/oral TXA. Direct comparisons of ATE for meta-analysis were not performed for THA or TKA studies because of a lack of 4 or more studies investigating the same TXA intervention. Therefore, direct meta-analysis was performed as a combined analysis of all hip and knee arthroplasty studies for IV and topical TXA.
TJA Results
Six randomized clinical trials compared IV TXA with a placebo, with equivalent rates of ATE reported of 0.9% and 0.5%, respectively (RR 1.40; 95% CI, 0.23-8.60; I 2 ¼ 0%; Fig. 4A) . Similarly, the metaanalysis of 5 randomized clinical trials that studied topical TXA showed the rate of ATE was 0.8% for both groups (RR 1.0; 95% CI, 0.18-5.71; I 2 ¼ 0%; Fig. 4B ).
Metaregression of VTE and ATE
The designation ASA status of 3 or higher among patients undergoing TKA had no significant impact on the risk of VTE; an analysis of the THA publications was not performed because of insufficient literature (Table 3 ). In addition, metaregression was performed for the subgroups of THA and TKA to assess for an influence on the VTE results based on the quality of the randomization, data reporting, and other biases of the included studies. None of these quality assessment appraisals had any significant impact on the target outcome of VTE, which helps provide validity to the quality of the studies included within the metaregression analysis (Table 3) .
Discussion
TXA is frequently used during THA and TKA to reduce blood loss and the need for allogeneic transfusion [3] . Although the efficacy of TXA has been well documented with numerous randomized clinical trials and subsequent meta-analyses, many anesthesiologists and orthopedic surgeons continue to have concerns regarding the safety of TXA. We performed a direct meta-analysis and metaregression analysis of 79 randomized clinical trials to investigate the risk of VTE and ATE complications in TJA patients receiving TXA to establish a basis for the combined clinical practice guidelines of AAHKS, AAOS, Hip Society, Knee Society, and ASRA. We found evidence demonstrating a lack of increased risk of VTE among patients administered TXA, even in patients who would be considered higher risk.
Although the systematic review and meta-analysis was limited primarily to the inclusion of only high-quality, level-I evidence studies, our research nonetheless has several limitations. First, investigation of an infrequent outcome that results in a conclusion of no statistical difference raises concern regarding the statistical power. When two populations of patients, despite a large sample size, have similar complication rates, a post-hoc power analysis will always demonstrate a lack of statistical power. When an examiner assumes two populations to be identical, it is not possible to obtain a statistically powered sample size. Therefore, we must imply that the aggregate of a large number of level-I evidence studies consistently presenting the same result suggests a limited possibility of stating that there is no statistical difference when in reality a difference does exist (type II error). Second, we performed analysis using combined patient populations of hip and knee arthroplasties, which provides the opportunity to introduce additional heterogeneity. However, the combination of hip and knee arthroplasties does not appear to have influenced the observed heterogeneity, because all individual and combined analyses have no statistical evidence of heterogeneity on I-squared testing. Third, we had insufficient data to perform subgroup analysis based on the type of surgery and the risk of ATE. However, we were able to perform a combined analysis of hip and knee arthroplasties. Fourth, we did not account for the type of postoperative VTE chemoprophylaxis because of the variable not consistently reported in all randomized clinical trials. Because other large institutional database investigations have demonstrated no effect on the risk of VTE with TXA use regardless of the type of VTE chemoprophylaxis, we do not believe it presents bias to alter the conclusions [2, 9] . Lastly, the interpretation of the results regarding the safety of TXA is limited by the inclusion and exclusion criteria used in the published literature. Because of concerns about the administration of TXA in high-risk patients, such as those with a history of thromboembolic and ischemic events as well as vascular stents, these patients were commonly excluded from randomized clinical trials. Because not all studies used the same inclusion and exclusion criteria, only a small number of the studies included in the current direct meta-analysis had higher-risk patients in their study population. Because we did not have the granularity to provide analysis of individual medical conditions, we attempted to perform a metaregression analysis to help draw conclusions regarding the risk of VTE in high-risk patients using ASA status as a proxy for comorbidity burden that would potentially be associated with an increased risk of a thromboembolic event. However, the use of ASA status is still not a precise tool for isolating patients with risk factors for a thromboembolic event.
In patients undergoing a hip or knee arthroplasty, IV, topical, and oral TXA lack any observed influence on the risk of VTE.
Concern has typically existed over the small sample sizes of individual randomized clinical trials and retrospective studies to accurately represent the lack of a difference between VTE rates of TXA administration and placebo. Prior investigation of the efficacy and safety of TXA, with a meta-analysis by Wei and Liu [94] , provided no evidence for an increased risk of VTE with the use of IV TXA in a population of 2720 hip and knee arthroplasty cases. To provide a larger patient population, hip and knee arthroplasty populations were combined in our study to give a population of 4268 cases for IV TXA and 3011 cases for topical TXA. When the populations of hip and knee arthroplasties are combined, the relative risk of VTE becomes closer to 1.0 than for the individual hip and knee arthroplasty meta-analyses. As a result, it provides strong evidence that the administration of TXA in patients without a history of thromboembolic events is not associated with an increased risk of VTE. Currently, safety concerns regarding administration of TXA to patients thought to be at "high-risk" of a thromboembolic event (eg, prior history of VTE, MI, CVA, or placement of a vascular stent) have limited the broad adoption of TXA among this patient population. Because of the limitations presented by the inclusion and exclusion criteria applied to each individual randomized clinical trial, a metaregression analysis was performed using ASA status as a proxy for patients at higher risk of VTE and ATE. Because patients with medical conditions placing them at a higher risk for thromboembolic events would typically be considered an ASA status 3 or 4, the demarcation of ASA status 3 or greater was used to classify a "high-risk" patient. In this study, we could only perform a metaregression analysis on the effects of ASA status on VTE for TKA patients. Our results suggest that patients with a higher ASA status do not carry an increased risk of VTE with TXA administration. To put this in perspective, the number of patients needed to potentially attribute a single VTE event to the administration of TXA was 983 patients. Alternatively, using the same patient population, the number needed to treat with IV TXA to prevent an allogeneic transfusion after a THA or TKA was only 4 and 3 patients, respectively. As a result, we would advocate for a multidisciplinary approach that considers each patient's individual risk profile along with the potential benefits of administering TXA.
As part of a broader investigation regarding the risk of VTE and mortality associated with the administration of TXA in the setting of TJA, Duncan et al [10] used the same demarcation for ASA status. Their retrospective database study of more than 13,000 TJA patients demonstrated no increased risk of symptomatic VTE with the administration of TXA in patients with an ASA status of 3 to 5 [10] . More recently, the results of a smaller, yet more focused, retrospective matched cohort database study on the use of TXA in patients with a history of VTE did not demonstrate an increased risk of VTE compared with the control group [9] . Similar to the current metaregression analysis, Whiting et al [11] in an institutional database study, demonstrated that utilization of TXA in patients with severe comorbidities (ASA status 3 or 4) did not increase the risk of VTE. Whiting et al [11] also noted that patients with severe comorbidities and additional risk factors for thromboembolic events were more likely to experience a symptomatic VTE; however, they were unable to show that the concomitant administration of TXA was associated with the increased risk of VTE.
In the case of ATE, no meta-analysis could be performed in the THA or TKA subgroups because of a lack of the requisite number of 4 or more studies investigating the same comparison within each subgroup. However, it is worth noting that all individual studies did not demonstrate significant difference in ATE rates between the administration of TXA and placebo. Because we were unable to perform meta-analysis of the individual subgroups, a combined TJA patient population underwent meta-analysis. Similar to VTE, the combined meta-analysis of hip and knee arthroplasties, regardless of the route of administration, showed no difference in the rates of ATE.
Conclusion
Based on this meta-analysis of 78 high-level randomized clinical trials, we conclude that the administration of TXA does not increase the risk of VTE in TJA patients. In addition, we did not observe a difference in the results between TKA and THA. However, based on the limited number of high-quality trials and gaps in the inclusion of "high-risk" patients within the available literature, we can only moderately support the same conclusion for TJA patients with an ASA score of 3 or higher, which was used as a proxy for higher-risk patients with increased comorbidity burden. Although limited data exists on the administration of TXA in "high-risk" patients, it should be considered that patients with a higher comorbidity burden may benefit the most from the reduction in blood loss associated with the administration of TXA. In light of the lack of evidence for harm, it seems prudent to consider its use on a more regular basis after evaluation of each patient's characteristics. 
